Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Multiple myeloma is a disease that causes increased bone fragility which is often revealed or complicated by vertebral fractures. Invasion of bone marrow by tumor plasma cells leads to bone destruction and reduced fat fraction. The main objective is to assess the correlation between vertebral bone marrow fat fraction and bone fragility represented by a severity score of vertebral fractures. The secondary objective is to assess the correlation with clinical and biological prognostic factors and scores..
Patients treated with vertebroplasty will be included during the period of the study, retrospectively or prospectively.
Mains collected data are represented by :
Not provided
Not provided
Not provided
Not provided
Not provided
| Label | Type | Description | Intervention Names |
|---|---|---|---|
| Multiple myeloma patients with vertebral fractures | Patients followed for multiple myeloma in the Lariboisière/Saint-Louis/Fernand-Widal hospital group, with vertebral fractures treated by vertebroplasty from January 2017 to December 2021, with recent clinical and biological data available at the time of imaging and fracture events |
|
| Name | Type | Description | Arm Group Labels | Other Names |
|---|---|---|---|---|
| Bone marrow fat quantification by MRI | Other | Bone marrow fat quantification by MRI at the moment of the diagnosis of vertebral fracture before treatment by vertebroplasty |
|
| Measure | Description | Time Frame |
|---|---|---|
| Percentage of bone marrow fat in vertebral bone marrow | Measured from Dixon sequences on MRI exams performed in routine care, for the assessment of the relationship between bone marrow vertebral fat content and the severity of the vertebral fractures | At the moment of the diagnosis of the vertebral fracture before treatment by vertebroplasty |
| Vertebral fracture severity score | Score established according to morphological criteria determined by MRI/computerized tomography scan, based on the Genant classification. Calculation of sum of the points awarded as follows: vertebral fracture on osteolytic lesion = 3; osteolytic lesion with high fracture risk = 0; other fracture related to increased bone fragility, scale 1-3 according to Genant's criteria, 3 representing the worst situation; normal vertebra = 0. | At the moment of the diagnosis of the vertebral fracture before treatment by vertebroplasty |
| Measure | Description | Time Frame |
|---|---|---|
| Sex | Male or female | At the moment of the diagnosis of the vertebral fracture before treatment by vertebroplasty |
| Age at the diagnosis of multiple myeloma | Age in years at the diagnosis of multiple myeloma |
Not provided
Inclusion Criteria:
Exclusion Criteria:
Not provided
Not provided
Not provided
Patients followed for multiple myelomas in the Lariboisière/Saint-Louis/Fernand-Widal hospital group, with vertebral fractures treated by vertebroplasty from January 2017 to December 2021, with recent clinical and biological data available at the time of imaging and fracture events.
| Name | Role | Phone | Extension | |
|---|---|---|---|---|
| Gregoire ATTANE, MD | Contact | +33 (0)688595952 | gregoire_attane@hotmail.com |
| Name | Affiliation | Role |
|---|---|---|
| Valérie BOUSSON, MD PhD | Assistance Publique - Hôpitaux de Paris | Principal Investigator |
| Facility | Status | City | State | ZIP | Country | Contacts |
|---|---|---|---|---|---|---|
| AP-HP, Lariboisière Hospital, Osteo-Articular, Visceral and Vascular Imaging department | Recruiting | Paris | 75010 | France |
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
| ID | Term |
|---|---|
| D009101 | Multiple Myeloma |
| D016103 | Spinal Fractures |
| ID | Term |
|---|---|
| D054219 | Neoplasms, Plasma Cell |
| D009370 | Neoplasms by Histologic Type |
| D009369 | Neoplasms |
| D020141 | Hemostatic Disorders |
Not provided
Not provided
Not provided
Not provided
Not provided
| At the moment of the diagnosis of the vertebral fracture before treatment by vertebroplasty |
| Weight/body mass index (BMI) | The Body Mass Index is calculated as the ratio between the weight measured in kilograms and the square of the height measured in meters | At the moment of the diagnosis of the vertebral fracture before treatment by vertebroplasty |
| Age at the moment of the vertebral fracture | Age in years at the moment of the vertebral fracture | At the moment of the diagnosis of the vertebral fracture before treatment by vertebroplasty |
| Type of the monoclonal component | Corresponding the type of the heavy (IgG, IgA, IgD, IgE or IgM) and/or the light chain (κ or λ) of the monoclonal immunoglobulin protein | At the moment of the diagnosis of the vertebral fracture before treatment by vertebroplasty |
| Serum rate of the monoclonal component | Serum rate of the monoclonal immunoglobulin protein in g/L | At the moment of the diagnosis of the vertebral fracture before treatment by vertebroplasty |
| Medullary plasmacytosis | Percentage of plasma cells assessed by bone marrow aspiration | At the moment of the diagnosis of the vertebral fracture before treatment by vertebroplasty |
| Presence of anaemia | Defined by hemoglobin value < 100g/L | At the moment of the diagnosis of the vertebral fracture before treatment by vertebroplasty |
| Presence of hypercalcemia | Defined by serum calcium > 2.75mmol/L | At the moment of the diagnosis of the vertebral fracture before treatment by vertebroplasty |
| Presence of renal failure related to myeloma | Defined by a creatinine clearance < 40mL/min or serum creatinine > 177µmol/L | At the moment of the diagnosis of the vertebral fracture before treatment by vertebroplasty |
| Presence of amyloidosis | Presence of amyloid deposits revealed by tissue biopsy | At the moment of the diagnosis of the vertebral fracture before treatment by vertebroplasty |
| Multiple myeloma stage according to the Salmon-Durie staging System | The Salmon-Durie classification in three stages according to the absence (I) or the presence (III) of the following criteria: anemia (hemoglobin value < 100g/L); hypercalcemia (serum calcium > 2.75mmol/L); amyloidosis (amyloid deposits revealed by biopsy); bone lesion at imaging. Concerning the serum rate of the monoclonal component, IgA < 30g/L and IgG < 50 g/L are considered stage I, and IgA > 50g/L and IgG > 70 g/L are considered stage III. The intermediate stage II is based on the rate of the blood monoclonal component (from 30 to 50 g/L for IgA and from 50 to 70 g/L for IgG) . The subclassification depends on the absence (A) or the presence of renal failure related to myeloma (B) (defined by creatinine clearance < 40mL/min or serum creatinine > 177µmol/L). | At the moment of the diagnosis of the vertebral fracture before treatment by vertebroplasty |
| Multiple myeloma stage according to the International Staging System (ISS) | To determine the International Staging System score (ISS) in three stages with stage I corresponding to serum beta-2-microglobulin < 3.5 mg/L and serum albumin ≥ 35 g/L, stage III corresponding to beta-2-microglobulin ≥ 5.5 mg/L, and stage II when not stage I or III | At the moment of the diagnosis of the vertebral fracture before treatment by vertebroplasty |
| Serum rate of Lactate dehydrogenase | Measured in U/L; serum lactate dehydrogenase is a poor prognosis factor when elevated (> 300U/L) | At the moment of the diagnosis of the vertebral fracture before treatment by vertebroplasty |
| Salmon-Durie Plus classification | Based of the MRI pattern of multiple myeloma that determine three stages : stage I (0-4 focal lesions), stage II (5-20 focal lesions), stage III (>20 focal lesions). The subclassification depends on the absence (A) or the absence of extramedullary disease (B) (anemia, hypercalcemia, renal failure, amyloidosis) | At the moment of the diagnosis of the vertebral fracture before treatment by vertebroplasty |
| Type of bone damage on CT scan | Classified as normal, focal lesion, diffuse osteopenia, focal lesion with diffuse osteopenia | At the moment of the diagnosis of the vertebral fracture before treatment by vertebroplasty |
| Vertebral radiodensity | Measured by a CT scan in Hounsfield Units | At the moment of the diagnosis of the vertebral fracture before treatment by vertebroplasty |
| D014652 |
| Vascular Diseases |
| D002318 | Cardiovascular Diseases |
| D010265 | Paraproteinemias |
| D001796 | Blood Protein Disorders |
| D006402 | Hematologic Diseases |
| D006425 | Hemic and Lymphatic Diseases |
| D006474 | Hemorrhagic Disorders |
| D008232 | Lymphoproliferative Disorders |
| D007160 | Immunoproliferative Disorders |
| D007154 | Immune System Diseases |
| D013124 | Spinal Injuries |
| D019567 | Back Injuries |
| D014947 | Wounds and Injuries |
| D050723 | Fractures, Bone |